Advances on diagnosis and treatment,of hepatic encepha lopathy

( views:, downloads: )
CAO Wu-kui(Tianjin Infectious Diseases Specialty Hospital,Tianjin 300192,China)
LIU Guo-wang(Tianjin Infectious Diseases Specialty Hospital,Tianjin 300192,China)
Journal Title:
Volume 2, Issue 01, 2009
Key Word:
Hepatic encephalopathy;Diagnosis;Treatment


  • [1]Mas A.Hepatic encephalopathy:from pathophysiology to treatment.Digestion,2006,73(Suppl 1):S86-S93.
  • [2]Feronci P,Lockwoed A,Mullen K,et al.Hepatic encephalopathy definition,nomenclature,diagnosis and quantifiication:final report of the working pany at the 11 th World Congresses of Gastroenterology Vienna.1998.Hepatology,2002,35:716-721.
  • [3]Collie A.Cognition in liver disease.Liver Int,2005,25(1):1-8.
  • [4]Choi CS,Kim BI,Lee MH,et al.The role of neurnpsychological testing and eleetnwncephalogram for early detection of minimal hepatic encephalupathy.Korean J Hepatol,2005,11(4):329-338.
  • [5]Matsusue E,Kinoshita T,Ohama E,el a1.Cerebral curtical and white matter lesions in chnmic hepatic em.ephalopathy:MRpathologic correlations.AJNR Am J Neummdiol,2005,26(2):347-351.
  • [6]Velissarls D,Solomou E,Kalogeropoulos A,et al.Sleep disorders anti brain MRI as early indicators of subclinical hepatic encephalopathy.Hepatogastroenterolngy,2006,53(67):51-54.
  • [7]Mechteheriakov S,Schocke M,Kugener A,et al.Chemical shift magnetic resonance spectroscopy of ciogulated grey matter in patients with minimal hepatic encephalopathy.Neuroradiology,2005,47(1):27-34.
  • [8]Qnero Guillrn JC,Herredas Gutiérrez JM.Diagnostic methods in hepatic encephalopathy.Clinical Chimica Aeta,2006,365(1-2):1-8.
  • [9]Hassanein TI,Hilsabeck RC,Perry W.Introduction to the hepatic encephalopathy scoring algorithm(HESA).Dig Dis Sci,2008,53(2):529-538.
  • [10]Shawcross D,Jalan R.Dispelling myths in the treatment of hepatic encephalopathy.Lancet,2005,365(9457):431-433.
  • [11]Vergara-Gómez M,Flaviá-Olivella M,Gil-Prades M,et al.Diagnosis and treatment of hepatic encephalopathy in Spain:results of a survey of hepatologists.Gastroenterol Hepatol,2006,29(1):1-6.
  • [12]Festi D,Vestito A,Mazzella G,et al.Management of hepatic encephalopathy:focus on antibiotic therapy.Digestion,2006,73(Suppl 1):94-101.
  • [13]Huang DB,DuPont HL.Rifaximin-a novel antimicrobial for enteric infection.J Infect,2005,50(2):97-106.
  • [14]Chen MF,Li RC,Chen CH,et al.Therapeutic effect of Lornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy.Di-Yi Junyi Daxue Xuebao,2005,25(6):718-719,722.(in Chinese)陈明妃,李如成,陈长虹,等.左旋门冬氨酸-鸟氨酸治疗肝硬化合并肝性脑病疗效观察.第一军医大学学报,2005,25(6):718-719,722.
  • [15]Malaguamera M,Pistone G,Elvira R,et al.Effects of L-carnitine in patients with hepatic encephalopathy.World J Gastroenterol,2005,11(45):7197-7202.
  • [16]Rüsch D,Forman SA.Classic benzodiazepines modulate the openclose equilibrium in alphal beta2gamma2L gamma-aminobutyric acid type A receptors.Anesthesiology,2005,102(4):783-792.
  • [17]Wijdicks EF,Nyberg SL.Prnpofol to control intracranial pressure in fnlminant hepatic failure.Transplant Proc,2002,34(4):1220-1222.
  • [18]Jacobi J,Fraser GL,Coursin DB,et al.Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult.Crit Care Med,2002,30(1):119-141.
  • [19]Novelli G,Rossi M,Pretagostini M,et al.One hundred sixteen cases of acute liver failure treated with MARS.Transplant Proc,2005,37(6):2557-2559.
  • [20]Braun C.Birck R,Singer MV,et al.Life-threatening intoxication with methylene bis(thiocyanate):clinical picture and pitfalls.A case report.BMC Emerg Med.2006,6:5.
  • [21]Saliba F.The molecular adsorbent recirculating system(MARS)in the intensive care unit:a rescue therapy for patients with hepatic failuro.Crit Care,2006,10(1):118.
  • [22]Doria C,Mandalá L,Scott VL,et al.Fulminant hepatic failure bridged to liver transplantation with a molecular adsorbent recirculating system:a single-center experience.Dig Dis Sci,2006,51(1):47-53.
  • [23]Stefoni S,Coil L,Bolondi L,et al.Molecular adsorbent recirculating system(MARS)application in liver failure:clinical and hemedepumtive results in 22 patients.Int J Artif Organs.2006,29(2):207-218.
  • [24]Shinoda M,Tiles AW,Kobayashi N,et al.A bioartificial liver device secreting interleukin-1 receptor antagonist for the treatment of hepatic failure in rats.J Surg Res,2007,137(1):130-140.
  • [25]Ng S,Han R,Chang S,et al.Impmved bepatocyte excretory function by immediate presentation of polarity cues.Tissue Eng,2006,12(8):2181-2191.
  • [26]Shineda M,TiRes AW,Wakabayashi G,et al.Troatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepahwytes producing interleukin-1 receptor antagonist.Tissue Eng,2006,12(5):1313-1323.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615